Our mission is to transform the clinical management of patients with cancer by developing and delivering innovative molecular imaging technologies to address unmet clinical needs, and reliably inform diagnosis and treatment decisions.
Our team is made up of industry leaders and experts in the field of radiopharmaceutical development and commercialisation.
Blue Earth Diagnostics is backed by Syncona Limited, a leading FTSE250 healthcare company focused on investing in and building global leaders in life science.
Find out how this technique works
Find out about prostate cancer
Cellular mechanisms for amino acid transport
Our research focus
Who we are
Who we work with
See how you can join the team
Where we are going to be
BURLINGTON, Mass. and OXFORD, UK, June 18, 2018 – Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced that presentations related to the clinical use of fluciclovine F...
Read More ›– Topline results presented at AUA 2018 evaluate clinical utility of 18F fluciclovine PET/CT imaging in men with recurrent prostate cancer following prior treatment – BURLINGTON, Mass. and OXFORD,...
Read More ›BURLINGTON, Mass. and OXFORD, UK, May 14, 2018 – Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced the upcoming presentation of initial results from the LOCATE clinical...
Read More ›– Unique attributes of rhPSMA and approved, commercially available Axumin® (fluciclovine F 18) for PET/CT together may provide expanded patient management options in biochemically recurrent prostate cancer – –...
Read More ›